Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and use thereof

摘要

The present invention relates to a pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human Metapneumovirus (hMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, wherein the agent is selected from monoclonal antibodies, biological or synthetic molecules. More specifically, the neutralizing agents are humanized anti-TSLP, anti-TSLPR, anti-OX40L and anti-CD177 monoclonal antibodies. The use of said composition for preparing a medicament for treating or ameliorating the symptoms and disease of patients infected with human Metapneumovirus (hMPV) is also described.